This article was originally published in Pharmaceutical Approvals Monthly
FDA issues "approvable" letter for the migraine treatment almotriptan Dec. 20. The NDA for the selective serotonin 5-HT receptor agonist was submitted Dec. 17, 1999
You may also be interested in...
Regulatory decision on migraine treatment almotriptan expected in second quarter. Pharmacia received an FDA "approvable" letter Dec. 20, 2000 (1"The Pink Sheet" Jan. 1, In Brief)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011